[Systemic treatment of advanced colorectal cancer].
The introduction of modern chemotherapeutic drugs and targeted therapies has substantially changed the treatment of advanced colorectal cancer (aCRC). Thus, median survival of stage IV patients was increased from 6 months under best supportive care to over 2 years if all drugs are administered. Also, new combination therapies may cause irresectable liver metastases to shrink to such an extent that they may be resected (downsizing). Patients who were formerly treated with palliative intent may now be cured. However, not all patients benefit from the new compounds. Very recently, new genetic characteristics were identified as potential molecular biomarkers that may predict response to anti-EGFR therapy, a specific targeted therapy; the marker detected is the mutational status of the oncogene k-ras. Only patients with wild-type k-ras-expressing tumors respond to anti-EGFR antibodies. The integration of biomarker analysis into the clinical routine represents an important step toward customized treatment of cancer patients.
Reinacher-Schick
A
A
Medizinische Universitätsklinik, Knappschaftskrankenhaus, In der Schornau 23-25, 44892 Bochum. anke.reinacher@rub.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016503:Drug Delivery Systems; D018773:Genes, erbB-1 / Q000235:genetics / Q000276:immunology; D011905:Genes, ras / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000556:secondary; D009367:Neoplasm Staging; D011379:Prognosis; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
J Clin Oncol. 2007 Apr 20;25(12):1539-44
17442997
J Clin Oncol. 2008 Apr 20;26(12):2006-12
18421053
Ann Oncol. 2004 Dec;15(12):1766-72
15550581
Z Gastroenterol. 2008 Aug;46(8):799-840
18759205
Z Gastroenterol. 2008 May;46(5):435-40
18461519
J Clin Oncol. 2007 May 1;25(13):1658-64
17470858
J Clin Oncol. 2008 Apr 10;26(11):1783-5
18398143
N Engl J Med. 2000 Sep 28;343(13):905-14
11006366
J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5
15467030
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 2008 Apr 20;26(12):2013-9
18421054
J Clin Oncol. 2006 Nov 1;24(31):4983-90
17075116
Internist (Berl). 2007 Jan;48(1):51-8
17160665
J Clin Oncol. 2007 Sep 20;25(27):4217-23
17548840
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
J Clin Oncol. 2008 Apr 1;26(10):1626-34
18316791
Ann Oncol. 2005 Aug;16(8):1311-9
15870084